#	Aladdin ID	Assay Type	Description	Organism	Compounds	Reference	BAO Format	Source
1.	ALA1054500	F	GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM	Plasmodium falciparum	13,467		organism-based format	GSK Malaria Screening
2.	ALA1054501	F	GSK_TCMDC: Inhibition of Plasmodium falciparum Dd2 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM	Plasmodium falciparum	13,467		organism-based format	GSK Malaria Screening
3.	ALA1054502	F	GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 LDH activity, using an LDH reporter assay. Test compounds present at 2uM	Plasmodium falciparum	13,467		organism-based format	GSK Malaria Screening
4.	ALA1054503	F	GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole erythrocytes, using parasite LDH activity as an index of growth.	Plasmodium falciparum	13,467		organism-based format	GSK Malaria Screening
5.	ALA1054504	F	GSK_TCMDC: Percent inhibition of human HepG2 cell line. Test compounds present at 10uM.	Homo sapiens	13,467		cell-based format	GSK Malaria Screening
6.	ALA1054505	F	GSK_TCMDC: Inhibition Frequency Index (IFI). The number of non-kinase HTS assays where a compound showed > 50 % inhibition, expressed as a percentage of the number of such assays in which the compound was tested		13,467		assay format	GSK Malaria Screening
7.	ALA2098495	F	GSK_TB: Intracellular minimum inhibitory concentration (MIC) BCG assay	Mycobacterium tuberculosis variant bovis BCG	776		organism-based format	GSK Tuberculosis Screening
8.	ALA2098496	F	GSK_TB: Intracellular minimum inhibitory concentration (MIC) H37Rv assay	Mycobacterium tuberculosis H37Rv	177		organism-based format	GSK Tuberculosis Screening
9.	ALA2098497	P	GSK_TB: GSK in-house hydrophobicity assay at pH7.4 (logD)		148		assay format	GSK Tuberculosis Screening
10.	ALA2098498	P	GSK_TB: GSK in-house hydrophobicity assay (logP)		148		assay format	GSK Tuberculosis Screening
11.	ALA2098499	A	GSK_TB: GSK in-house kinetic solubility assay. DMSO stock solution diluted to 100 ml with pH 7.4 phosphate buffered saline.		157		assay format	GSK Tuberculosis Screening
12.	ALA3431450	F	GSK_TCAKS: pIC50 Leishmania donovani viability assay using fluorescence intensity. Assay plates (1536-well) were prepared by adding 30nL per well of compound. For single shot assay, the final compound concentration was 5uM. For potency determinations, eleven-point one in three dilution curves were generated with a top concentration of 50uM. Briefly, eGFP LdBOB axenic amastigotes were harvested, fixed and counted in a CASY cell counter (Roche-Applied Science). A final concentration of 1.5 * 10^5 cells per well were prepared in amastigote media containing 500 U/mL penicillin/streptomycin (Invitrogen) and 6uL was dispensed to each experimental well using a Multidrop Combi dispenser (Thermo Scientific). 6uL of assay media was dispensed to control columns used as reference for 100% compound response. Following incubation for 72 h at 37C, 5% CO2, 2 uL of resazurin was added to each well at a final concentration of 0.5 mM in phosphate buffered saline (PBS) with IGEPAL (Sigma-Aldrich), 0.05% (v/v). The plates were incubated for 4 h at room temperature and resorufin fluorescence was detected using a PerkinElmer EnVision plate reader with excitation at 528 nm and emission at 590 nm.	Leishmania donovani	590		organism-based format	GSK Kinetoplastid Screening
13.	ALA3431451	F	GSK_TCAKS: pIC50 Leishmania donovani Imaging: Infected Macrophages. Assay plates (384-well) were prepared by adding 250nL of compound to each well. For single shot assay, the final compound concentration was 5 uM. For potency determinations, eleven-point one in three dilution curves were generated with a top concentration of 50 uM. Two exposure images were taken for each well using 405 nm and 488 nm laser excitation. Automated image analysis was performed with a script developed on Acapella High Content Imaging and Analysis Software (PerkinElmer). Output: Percent of infected macrophage cells were reported for each well.	Homo sapiens	592		organism-based format	GSK Kinetoplastid Screening
14.	ALA3431452	F	GSK_TCAKS: pIC50 Leishmania donovani Imaging: Amastigotes/Macrophages. Assay plates (384-well) were prepared by adding 250nL of compound to each well. For single shot assay, the final compound concentration was 5 uM. For potency determinations, eleven-point one in three dilution curves were generated with a top concentration of 50 uM. Two exposure images were taken for each well using 405 nm and 488 nm laser excitation. Automated image analysis was performed with a script developed on Acapella High Content Imaging and Analysis Software (PerkinElmer). Output: Average number of amastigotes per macrophage cell were reported for each well.	Homo sapiens	588		organism-based format	GSK Kinetoplastid Screening
15.	ALA3431453	F	GSK_TCAKS: pIC50 Leishmania donovani Imaging: THP-1 Host Macrophages. Assay plates (384-well) were prepared by adding 250nL of compound to each well. For single shot assay, the final compound concentration was 5 uM. For potency determinations, eleven-point one in three dilution curves were generated with a top concentration of 50 uM. Two exposure images were taken for each well using 405 nm and 488 nm laser excitation. Automated image analysis was performed with a script developed on Acapella High Content Imaging and Analysis Software (PerkinElmer). Output: THP-1 cell count were reported for each well.	Homo sapiens	591		organism-based format	GSK Kinetoplastid Screening
16.	ALA3431456	T	GSK_TCAKS: pIC50 HepG2 human cell line viability assay using luminiscence. Actively growing HepG2 cells were removed from a T-175 TC flask using 5mL Eagle's MEM (containing 10% FBS, 1% NEAA, 1% penicillin/streptomycin) and dispersed in the medium by repeated pipetting. Seeding density was checked to ensure that new mono-layers were not more than 50% confluent at the time of harvesting. Cell suspension was added to 500 mL of the same medium at a final density of 1.2 * 10^5 cells/mL. This cell suspension was dispensed (25 uL, 3000 cells per well) into 384-well clear-bottom plates using a Multidrop Combi dispenser. Prior to addition of the cell suspension, the screening compounds (250 nL) were pre-dispensed into the plates with an Echo liquid handler. Plates were incubated for 48 h at 37C, 5% CO2. After incubation, plates equilibrated at room temperature for 30 min before proceeding to develop the luminescent signal. The signal developer, CellTiter-Glo Reagent, was allowed to equilibrate at room temperature for 30 min and added to the plates (25uL per well) using a Multidrop Combi dispenser. Plates were left for 10 min at room temperature for stabilization and then read using a ViewLux.	Homo sapiens	592		cell-based format	GSK Kinetoplastid Screening
17.	ALA3431458	F	GSK_TCAKS: pIC50 CYP51 from Trypanosoma cruzi.	Trypanosoma cruzi	584		assay format	GSK Kinetoplastid Screening
18.	ALA3436042	F	ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmGLUT1 that are glucose transport deficient and complemented with the human glucose transporter GLUT1. Activity is measured by DNA content using SYBR green in vitro	Leishmania mexicana	13,179		assay format	St Jude Leishmania Screening
19.	ALA3436043	F	ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmPfHT that are glucose transport deficient and complemented with the Plasmodium falciparum hexose transporter. Activity is measured by by DNA content using SYBR green in vitro	Leishmania mexicana	13,179		assay format	St Jude Leishmania Screening
20.	ALA3436044	F	ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmGT2 that are glucose transport deficient and complemented with the L. Mexicana glucose transporter 2. Activity is measured by by DNA content using SYBR green in vitro	Leishmania mexicana	13,179		assay format	St Jude Leishmania Screening